Prachi Mehta
@prachi.0390
Udaipur
8+ Years of experience
SEBI Registration INH000017879CA Prachi Mehta, a SEBI Registered Research Analyst with over 8 years of experience in the financial markets. Our group specializes in delivering stock recommendations rooted in comprehensive sectoral analysis and systematic quantitative stock selection. We focus on short-term momentum trading, with holding periods ran ... Read more
Trade Ideas
186
Opinions
531
Followers
4k
Expertise
Quantitative
Swing Trading
Market Commentry
Past Trade View Performance
Total Trades
179
Missed Trades
123
Profit Trades
56
31.2% Hit Rate
Ask me Anything
Got a question? Ask me and I will answer it. Stay curious, stay hungry!
Posts
shared an insight ⚡️ 9th May
TATAMOTORS
Soaring high : 9 may 2025TATAMOTORS
is currently trading at Rs. 706.50, up by 24.60 points or 3.61% from its previous closing of Rs. 681.90 on the BSE.
The scrip opened at Rs. 662.60 and has touched a high and low of Rs. 709.00 and Rs. 662.60 respectively. So far 2194837 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1179.05 on 30-Jul-2024 and a 52 week low of Rs. 542.55 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 710.85 and Rs. 639.95 respectively. The current market cap of the company is Rs. 259682.34 crore.
The promoters holding in the company stood at 42.58%, while Institutions and Non-Institutions held 35.04% and 22.39% respectively.
Tata Motors has launched registered vehicle scrapping facility (RVSF) in Kolkata. This marks the launch of the company’s eighth RVSF across the country. Named ‘***** - Recycle with Respect,’ this cutting-edge facility is designed to sustainably and safely dismantle up to 21,000 end-of-life vehicles annually. The RVSF will be operated by Tata Motors’ partner, Selladale Synergies India, and is equipped to handle the scrapping of passenger and commercial vehicles, along with two-wheelers and three-wheelers, across all brands.
Each ***** facility is fully digitalised, with all its operations seamless and paperless. Equipped with cell-type dismantling for commercial vehicles, two-wheelers and three-wheelers, and line-type dismantling for passenger vehicles, there are dedicated stations for the safe dismantling of various components, including tyres, batteries, fuel, oils, liquids, and gases.
Tata Motors is India’s largest automobile company. Through subsidiaries and associate companies, Tata Motors has operations in the UK, South Korea, Thailand, South Africa and Indonesia. Among them is Jaguar Land Rover, the business comprising the two iconic British brands. shared an insight ⚡️ 9th May
Major update for Investors of
LUPIN
LUPIN
is currently trading at Rs. 2033.50, up by 19.70 points or 0.98% from its previous closing of Rs. 2013.80 on the BSE.
The scrip opened at Rs. 1989.20 and has touched a high and low of Rs. 2047.80 and Rs. 1976.30 respectively. So far 12387 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1493.75 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs. 2099.85 and Rs. 1976.30 respectively. The current market cap of the company is Rs. 93047.04 crore.
The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 46.88% and 6.20% respectively.
LUPIN
has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Raltegravir Tablets USP, 600 mg. Raltegravir Tablets are bioequivalent to Isentress HD Tablets, 600 mg of Merck Sharp & Dohme LLC. Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin’s Nagpur facility in India.
Raltegravir Tablets USP, 600 mg are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients and in pediatric patients weighing at least 40 kg. Raltegravir Tablets USP, 600 mg (RLD Isentress HD) had an estimated annual sale of $34 million in the U.S. (IQVIA MAT March 2025).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. shared an insight ⚡️ 9th May
Stocks in News today : 9 May 2025
ZYDUSLIFE
has received final approval from the United States Food and Drug Administration (USFDA) for Glatiramer Acetate Injection, 20 mg/mL and 40 mg/mL, single-dose prefilled syringes. Zydus’ generic Glatiramer Acetate Injection is an FDA-approved, AP-rated substitutable generics of Copaxone 20 mg/ml, 40 mg/ml and indicated for the treatment of relapsing forms of Multiple Sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Venus Pipes & Tubes has received LOI from one of India’s leading integrated power plant equipment manufacturers for Stainless Steel Seamless Boiler Tubes used in series of Supercritical and Subcritical Thermal Power Projects worth around Rs 190 crore (excluding GST). Formal order will be released shortly and is expected to be executed progressively during next 12-15 months.
INDIGO
(IndiGo) has inked an agreement with Norwegian low-cost carrier Norse Atlantic Airways for damp leasing two more Boeing Dreamliner 787- aircraft bolstering its wide-body fleet. Norse Atlantic in November last year had announced signing a Letter of Intent for six such planes with a reputable airline. IndiGo is expanding its international footprint with plans to launch direct flights to Europe amid the rising international traffic from India.
LUPIN
has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Raltegravir Tablets USP, 600 mg. Raltegravir Tablets are bioequivalent to Isentress HD Tablets, 600 mg of Merck Sharp & Dohme LLC. Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin’s Nagpur facility in India.FAQ's
What are the top stock recommendations by Prachi Mehta?
Prachi Mehta provides expert stock recommendations based on in-depth market analysis, financial trends, and industry insights. Their top stock picks include companies with strong fundamentals, growth potential, and market resilience. Stay updated with Prachi Mehta's latest recommendations on their StockGro profile.
How can I follow Prachi Mehta's latest investment insights?
You can follow Prachi Mehta's latest investment insights, stock recommendations, and market analysis on StockGro app. Additionally, you can check their detailed stock analysis reports in the StockGro blog section.
What is Prachi Mehta's investment strategy?
Prachi Mehta follows a data-driven, research-backed investment strategy focused on maximizing returns while managing risk. Their approach includes fundamental and technical analysis, portfolio diversification, and sectoral trends to identify high-potential stocks.
How long has Prachi Mehta been a SEBI-registered Research Analyst (RA)?
Prachi Mehta has been a SEBI-registered Research Analyst and have 8+ Years of experience. With extensive experience in stock market analysis and investment research, they have guided investors in making informed and profitable decisions.
Where can I see Prachi Mehta's past performance and stock picks?
You can check Prachi Mehta's past stock recommendations, success rate, and investment insights on their StockGro profile. Their historical stock picks reflect a track record of strategic investment decisions based on thorough research.
How can I contact Prachi Mehta for stock market advice?
For stock market guidance from Prachi Mehta, you can connect through their StockGro profile. Some RAs may also provide personalized investment consultations based on their availability and SEBI regulations.
What is Prachi Mehta's track record in predicting market movements?
Prachi Mehta has a proven track record of accurate market analysis and trend predictions. By analyzing economic indicators, market sentiment, and technical charts, they have consistently helped investors make well-timed investment decisions.
What is the SEBI Registration number for Prachi Mehta?
Prachi Mehta is a SEBI-registered Research Analyst with the SEBI Registration INH000017879. This ensures that their investment recommendations comply with SEBI's regulatory framework for investor protection and financial advisory standards.
Be Financially Free with StockGro